Industry Payments to Congress
The pharmaceutical industry in the USA contributed funds totaling $6.5 million to Members of Congress during the period from 1991 to the first quarter of 1994, according to a new study published by the Center for Public Integrity.
A total of $5 million was contributed by the drug industry over this period to Political Action Committees, and the biggest PAC contributors were Glaxo and Pfizer, says the study. Glaxo contributed $173,540 during 1993 through to first-quarter 1994, and a total of $495,013 to PACs and the parties during 1991-94, while Pfizer contributed $139,992 to PACs from 1991 to first-quarter 1994 and a total of $501,104 to PACs and the parties during 1991-94.
Other campaign contributions made by pharmaceutical companies during 1991-94 included $274,050 from Schering-Plough, $237,250 from Merck & Co, $236,170 from SmithKline Beecham, $228,400 from Ciba-Geigy, $227,539 from Eli Lilly and $220,304 from Syntex.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze